By Dr Briony Kate Larance

Journal articles

Darke S; Farrell M; Duflou J; Larance B; Lappin J, 2019, 'Circumstances of death of opioid users being treated with naltrexone', Addiction, 114, pp. 2000 - 2007, http://dx.doi.org/10.1111/add.14729

Campbell G; Larance B; Lintzeris N, 2019, 'Regulatory and other responses to the pharmaceutical opioid problem', Medical Journal of Australia, 211, pp. 237 - 237.e1, http://dx.doi.org/10.5694/mja2.50303

Shanahan M; Larance B; Nielsen S; Cohen M; Schaffer M; Campbell G, 2019, 'A protocol for a discrete choice experiment: Understanding patient medicine preferences for managing chronic non-cancer pain', BMJ Open, 9, http://dx.doi.org/10.1136/bmjopen-2018-027153

Kelly PJ; Beck AK; Baker AL; Deane FP; Hides L; Manning V; Shakeshaft A; Larance B; Neale J; Kelly J; Oldmeadow C; Searles A; Treloar C; Gray RM; Argent A; McGlaughlin R, 2019, 'Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in Mutual Support Groups Coordinated by SMART Recovery Australia: Protocol for a Pilot Study (Preprint)', , http://dx.doi.org/10.2196/preprints.15113

Larance B; Campbell G; Moore T; Nielsen S; Bruno R; Lintzeris N; Cohen M; Hall W; Mattick R; O'Donnell C; Degenhardt L, 2019, 'Concerns and help-seeking among patients using opioids for management of chronic noncancer pain', Pain Medicine United States, 20, pp. 758 - 769, http://dx.doi.org/10.1093/pm/pny078

Gisev N; Pearson SA; Larance B; Larney S; Blanch B; Degenhardt L, 2019, 'A population-based study of transdermal fentanyl initiation in Australian clinical practice', European Journal of Clinical Pharmacology, 75, pp. 401 - 408, http://dx.doi.org/10.1007/s00228-018-2588-0

Peacock A; Larance B; Bruno R; Pearson SA; Buckley NA; Farrell M; Degenhardt L, 2019, 'Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations', Addiction, 114, pp. 404 - 405, http://dx.doi.org/10.1111/add.14556

Peacock A; Larance B; Bruno R; Pearson SA; Buckley NA; Farrell M; Degenhardt L, 2019, 'Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting', Addiction, 114, pp. 389 - 399, http://dx.doi.org/10.1111/add.14380

Jacka B; Kemp R; Degenhardt L; Peacock A; Clare P; Bruno R; Dev A; Sotade O; Larance B, 2019, 'Trends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007–2015', Drug and Alcohol Review, 38, pp. 159 - 168, http://dx.doi.org/10.1111/dar.12908

Schaffer AL; Karanges EA; Buckley NA; Wilson A; Degenhardt L; Larance B; Pearson SA, 2019, 'Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study', Pharmacoepidemiology and Drug Safety, 28, pp. 97 - 105, http://dx.doi.org/10.1002/pds.4683

Campbell G; Lintzeris N; Gisev N; Larance B; Pearson S; Degenhardt L, 2019, 'Regulatory and other responses to the pharmaceutical opioid problem', Medical Journal of Australia, 210, pp. 6 - e1, http://dx.doi.org/10.5694/mja2.12047

Nielsen S; Lintzeris N; Murnion B; Degenhardt L; Bruno R; Haber P; Johnson J; Hardy M; Ling S; Saddler C; Dunlop A; Demirkol A; Silsbury C; Phung N; Houseman J; Larance B, 2018, 'Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence', Drug and Alcohol Review, 37, pp. 887 - 896, http://dx.doi.org/10.1111/dar.12859

Pikovsky M; Peacock A; Larney S; Larance B; Conroy E; Nelson E; Degenhardt L, 2018, 'Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study', Drug and Alcohol Dependence, 188, pp. 304 - 310, http://dx.doi.org/10.1016/j.drugalcdep.2018.04.016

Campbell G; Hall WD; Peacock A; Lintzeris N; Bruno R; Larance B; Nielsen S; Cohen M; Chan G; Mattick RP; Blyth F; Shanahan M; Dobbins T; Farrell M; Degenhardt L, 2018, 'Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study', Lancet Public Health, 3, pp. e341 - e350, http://dx.doi.org/10.1016/S2468-2667(18)30110-5

Griffiths S; Jacka B; Degenhardt L; Murray SB; Larance B, 2018, 'Physical appearance concerns are uniquely associated with the severity of steroid dependence and depression in anabolic–androgenic steroid users', Drug and Alcohol Review, 37, pp. 664 - 670, http://dx.doi.org/10.1111/dar.12688

Blanch B; Degenhardt L; Buckley NA; Gisev N; Dobbins T; Karanges EA; Larance B; Larney S; Pearson SA, 2018, 'Prescription opioid access patterns and factors associated with increasing number of prescribers, pharmacies, and dispensings: An observational study using pharmaceutical claims', Pain Medicine United States, 19, pp. 1170 - 1183, http://dx.doi.org/10.1093/pm/pnx035

Gisev N; Pearson SA; Karanges EA; Larance B; Buckley NA; Larney S; Dobbins T; Blanch B; Degenhardt L, 2018, 'To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?', Pharmacoepidemiology and Drug Safety, 27, pp. 550 - 555, http://dx.doi.org/10.1002/pds.4329

Larance B; Gisev N; Cama E; Nelson EC; Darke S; Larney S; Degenhardt L, 2018, 'Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence', Drug and Alcohol Dependence

Schaffer A; Buckley NA; Degenhardt L; Larance B; Cairns R; Dobbins T; Pearson SA, 2018, 'Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia', Canadian Medical Association Journal, 190, pp. E355 - E362, http://dx.doi.org/10.1503/cmaj.170666

Gisev N; Larance B; Cama E; Nielsen S; Roxburgh A; Bruno R; Degenhardt L, 2018, 'A nationwide study of the extent and factors associated with fentanyl use in Australia', Research in Social and Administrative Pharmacy, 14, pp. 303 - 308, http://dx.doi.org/10.1016/j.sapharm.2017.04.002

Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L, 2018, 'Knowledge of opioid overdose and attitudes to supply of take-home naloxone among people with chronic noncancer pain prescribed opioids', Pain Medicine United States, 19, pp. 533 - 540, http://dx.doi.org/10.1093/pm/pnx021

Peacock A; Larance B; Farrell M; Cairns R; Buckley N; Degenhardt L, 2018, 'Opioid use and harms associated with a sustained-release tapentadol formulation: A postmarketing study protocol', BMJ Open, 8, http://dx.doi.org/10.1136/bmjopen-2017-020006

Cooper S; Campbell G; Larance B; Murnion B; Nielsen S, 2018, 'Perceived stigma and social support in treatment for pharmaceutical opioid dependence', Drug and Alcohol Review, 37, pp. 262 - 272, http://dx.doi.org/10.1111/dar.12601

Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L, 2018, 'The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study', Lancet Psychiatry, 5, pp. 155 - 166, http://dx.doi.org/10.1016/S2215-0366(18)30003-8

Holliday S; Hayes C; Dunlop A; Morgan S; Tapley A; Henderson K; Larance B; Magin P, 2017, 'Protecting pain patients. The evaluation of a chronic pain educational intervention', Pain Medicine United States, 18, pp. 2306 - 2315, http://dx.doi.org/10.1093/pm/pnx018

Larance B; Degenhardt L; Peacock A; Gisev N; Mattick R; Colledge S; Campbell G, 2017, 'Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses', Drug and Alcohol Review, http://dx.doi.org/10.1111/dar.12617

Jacka B; Peacock A; Degenhardt L; Bruno R; Clare P; Kemp R; Dev A; Larance B, 2017, 'Trends in PIEDs use among male clients of needle–syringe programs in Queensland, Australia; 2007–2015', International Journal of Drug Policy, 46, pp. 74 - 78, http://dx.doi.org/10.1016/j.drugpo.2017.05.048

Nielsen S; Gisev N; Bruno R; Hall W; Cohen M; Larance B; Campbell G; Shanahan M; Blyth F; Lintzeris N; Pearson S; Mattick R; Degenhardt L, 2017, 'Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment', Pharmacoepidemiology and Drug Safety, 26, pp. 587 - 591, http://dx.doi.org/10.1002/pds.4168

Nielsen S; Larance B; Lintzeris N, 2017, 'Opioid agonist treatment for patients with dependence on prescription opioids', JAMA Journal of the American Medical Association, 317, pp. 967 - 968, http://dx.doi.org/10.1001/jama.2017.0001

Nielsen S; Larance B; Degenhardt L; Gowing L; Lintzeris N, 2017, 'A systematic review of opioid agonist treatments for pharmaceutical opioid dependence', DRUG AND ALCOHOL DEPENDENCE, 171, pp. E152 - E153, http://dx.doi.org/10.1016/j.drugalcdep.2016.08.421

Campbell G; Bruno R; Cohen M; Hall W; Nielsen S; Lintzeris N; Larance B; Mattick RP; Farrell M; Degenhardt L, 2017, 'Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic non-cancer pain: Different measures, same patients?', DRUG AND ALCOHOL DEPENDENCE, 171, pp. E33 - E33, http://dx.doi.org/10.1016/j.drugalcdep.2016.08.103

Peacock A; Bruno R; Larance B; Lintzeris N; Ali R; Oen D; Sotade O; White N; Degenhardt L, 2017, 'Same-day use of opioids and depressants: A retrospective diary study', DRUG AND ALCOHOL DEPENDENCE, 171, pp. E161 - E161, http://dx.doi.org/10.1016/j.drugalcdep.2016.08.444

Larney S; Cama E; Nelson E; Larance B; Degenhardt L, 2016, 'A cross-sectional study of correlates of imprisonment in opioid-dependent men and women in New South Wales, Australia', Drug and Alcohol Review, 35, pp. 686 - 692, http://dx.doi.org/10.1111/dar.12357

Peacock A; Nielsen S; Bruno R; Campbell G; Larance B; Degenhardt L; Peacock A, 2016, 'Geographic variation in health service use and perceived access barriers for Australian adults with chronic non-cancer pain receiving opioid therapy', Pain Medicine United States, 17, pp. 2003 - 2016, http://dx.doi.org/10.1093/pm/pnw109

Deacon RM; Nielsen S; Leung S; Rivas G; Cubitt T; Monds LA; Ezard N; Larance B; Lintzeris N, 2016, 'Alprazolam use and related harm among opioid substitution treatment clients – 12 months follow up after regulatory rescheduling', International Journal of Drug Policy, 36, pp. 104 - 111, http://dx.doi.org/10.1016/j.drugpo.2016.06.006

Larance B; Copeland J; Burns L; Holden J; Farrell M; Degenhardt L, 2016, 'PHYSICAL HEALTH AND OPPORTUNITIES FOR INTERVENTION AMONG MEN WHO USE PERFORMANCE AND IMAGE ENHANCING DRUGS', DRUG AND ALCOHOL REVIEW, 35, pp. 47 - 48, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398381500129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peacock A; Bruno R; Larance B; Lintzeris N; Nielsen S; Ali R; Dobbins T; Degenhardt L; Peacock A, 2016, 'Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study', Drug and Alcohol Dependence, 166, pp. 125 - 133, http://dx.doi.org/10.1016/j.drugalcdep.2016.07.003

Campbell G; Bruno R; Lintzeris N; Cohen M; Nielsen S; Hall W; Larance B; Mattick RP; Blyth F; Farrell M; Degenhardt L, 2016, 'Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: Do different measures identify the same patients?', Pain, 157, pp. 1489 - 1498, http://dx.doi.org/10.1097/j.pain.0000000000000548

Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N, 2016, 'Opioid agonist treatment for pharmaceutical opioid dependent people', Cochrane Database of Systematic Reviews, 2016, pp. cd011117, http://dx.doi.org/10.1002/14651858.CD011117.pub2

Larance B; Campbell G; Peacock A; Nielsen S; Bruno R; Hall W; Lintzeris N; Cohen M; Degenhardt L; Peacock A, 2016, 'Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy', Drug and Alcohol Dependence, 162, pp. 79 - 87, http://dx.doi.org/10.1016/j.drugalcdep.2016.02.048

Degenhardt L; Gisev N; Cama E; Nielsen S; Larance B; Bruno R, 2016, 'The extent and correlates of community-based pharmaceutical opioid utilisation in Australia', Pharmacoepidemiology and Drug Safety, 25, pp. 521 - 538, http://dx.doi.org/10.1002/pds.3931

Gisev N; Nielsen S; Cama E; Larance B; Bruno R; Degenhardt L, 2016, 'An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia', European Journal of Clinical Pharmacology, 72, pp. 469 - 494, http://dx.doi.org/10.1007/s00228-015-1995-8

Larance B; Bruno R; Lintzeris N; Degenhardt L; Black E; Brown A; Nielsen S; Dunlop A; Holland R; Cohen M; Mattick RP, 2016, 'Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale', Drug and Alcohol Dependence, 159, pp. 42 - 52, http://dx.doi.org/10.1016/j.drugalcdep.2015.11.026

Larance B; Mattick R; Ali R; Lintzeris N; Jenkinson R; White N; Kihas I; Cassidy R; Degenhardt L, 2016, 'Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia', Drug and Alcohol Review, 35, pp. 83 - 91, http://dx.doi.org/10.1111/dar.12344

Gisev N; Pearson SA; Blanch B; Larance B; Dobbins T; Larney S; Degenhardt L, 2016, 'Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated', British Journal of Clinical Pharmacology, pp. 1123 - 1133, http://dx.doi.org/10.1111/bcp.13026

Lintzeris N; Moodley R; Campbell G; Larance B; Bruno R; Nielsen S; Degenhardt L, 2016, 'Sleep quality among people living with chronic noncancer pain: Findings from the pain and opioids in treatment (POINT) cohort', Clinical Journal of Pain, 32, pp. 380 - 387, http://dx.doi.org/10.1097/AJP.0000000000000282

White N; Ali R; Larance B; Zador D; Mattick RP; Degenhardt L, 2016, 'The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film', Drug and Alcohol Review, 35, pp. 76 - 82, http://dx.doi.org/10.1111/dar.12317

Peacock AK; Degenhardt L; Campbell G; Larance B; Nielsen S; Hall W; Mattick RP; Bruno R; Peacock A, 2016, 'A typology of predictive risk factors for non-adherent medication-related behaviors among chronic non-cancer pain patients prescribed opioids: a cohort study', Pain Physician, 19, pp. e421 - e434, http://dx.doi.org/10.36076/ppj/2019.19.e421

Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R, 2015, 'A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone', Pharmacoepidemiology and Drug Safety, 24, pp. 1321 - 1333, http://dx.doi.org/10.1002/pds.3883

White N; Flaherty I; Higgs P; Larance B; Nielsen S; Degenhardt L; Ali R; Lintzeris N, 2015, 'Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study', Drug and Alcohol Review, 34, pp. 623 - 629, http://dx.doi.org/10.1111/dar.12308

Back to profile page